Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | The potential of targeting CD123 in myeloid malignancies

Anand Patel • 6 Jun 2023
ASCO 2023
Acute Myeloid Leukemia Leukemia CAR-NK CAR-T SAR443579 Tagraxofusp

Anand Patel, MD, University of Chicago, Chicago, IL, discusses the potential of targeting CD123 with immunotherapy in myeloid malignancies, highlighting promising CD123-targeting agents such as SAR443579, a natural killer (NK) cell engager currently under evaluation in an early phase clinical trial. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Anand Patel

Randomized study of ASTX727 with or without iadademstat in accelerated/blast-phase MPNs
2:40
Randomized study of ASTX727 with or without iadademstat in accelerated/blast-phase MPNs
Anand Patel • 25 Nov 2025
Phase Ib trial of ivosidenib plus ruxolitinib in IDH1-mutated advanced MPNs
2:05
Phase Ib trial of ivosidenib plus ruxolitinib in IDH1-mutated advanced MPNs
Anand Patel • 25 Nov 2025
Insights on menin inhibition and emerging strategies to improve response and MRD outcomes in AML
2:48
Insights on menin inhibition and emerging strategies to improve response and MRD outcomes in AML
Anand Patel • 25 Nov 2025
Primary efficacy analysis of TKI and inotuzumab ozogamicin-based therapy for newly diagnosed Ph+ ALL
4:18
Primary efficacy analysis of TKI and inotuzumab ozogamicin-based therapy for newly diagnosed Ph+ ALL
Anand Patel • 25 Nov 2025

Related Videos

Is there a role for CAR T-cell therapy in the treatment pathway for CLL?
1:21
Is there a role for CAR T-cell therapy in the treatment pathway for CLL?
Marco Ruella • 16 Oct 2026
Access challenges to diagnosis and treatment for patients with CLL in resource-restricted countries
1:45
Access challenges to diagnosis and treatment for patients with CLL in resource-restricted countries
Celso Arrais • 17 Oct 2026
Insights into the current CLL treatment algorithm and emerging research directions
1:51
Insights into the current CLL treatment algorithm and emerging research directions
Matthew Davids • 17 Oct 2026
How has the harmonization of genomic profiling in Sweden impacted patient access to CLL diagnostics?
1:21
How has the harmonization of genomic profiling in Sweden impacted patient access to CLL diagnostics?
Richard Rosenquist • 17 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals